布地格福与茚达特罗格隆溴铵治疗慢性阻塞性肺疾病的疗效比较

Comparison of the efficacy of budesonide/glycopyrrolate/formoterol fumarate and indacaterol/glycopyrrolate in the treatment of chronic obstructive pulmonary disease

摘要:

目的 探讨布地格福与茚达特罗格隆溴铵治疗慢性阻塞性肺疾病（COPD）的疗效。方法 选取2022年1月—2022年12月阜阳市人民医院收治的100例COPD患者，以随机数表法分为对照组和研究组，每组50例。对照组给予布地格福吸入气雾剂，研究组给予茚达特罗格隆溴铵吸入粉雾剂，连续治疗12周评估疗效。对比两组肺功能、临床疗效、气道重塑指标、炎症因子、免疫功能及药物不良反应发生情况。结果 两组治疗前后用力肺活量、最大呼气峰流速、第1秒用力呼气容积/用力肺活量的差值比较，差异均无统计学意义（P >0.05）。两组总有效率比较，差异无统计学意义（P >0.05）。两组治疗前后气道壁厚度/外径比值、气道面积/总横截面积比值的差值比较，差异均无统计学意义（P >0.05）。两组治疗前后C反应蛋白、淀粉样蛋白、白细胞介素-17的差值比较，差异均无统计学意义（P >0.05）。对照组、研究组治疗前后CD4⁺/CD8⁺的差值比较，差异无统计学意义（P >0.05）。两组总不良反应发生率比较，差异无统计学意义（P >0.05）。结论 布地格福与茚达特罗格隆溴铵治疗COPD的疗效相当，均可明显改善患者肺功能，抑制炎症反应，改善免疫功能，抗气道重塑，且安全性良好。

Abstract:

Objective To compare the efficacy of budesonide/ glycopyrrolate/ formoterol fumarate and indacaterol/ glycopyrrolate in the treatment of chronic obstructive pulmonary disease (COPD).Methods A total of 100 patients with COPD admitted to our hospital from January 2022 to December 2022 were selected, and were divided into the control group and the study group by the random number table method, with 50 cases in each group. The control group was treated with budesonide/glycopyrrolate/formoterol fumarate inhalation aerosol, and the study group was given indacaterol/glycopyrrolate inhalation powder. The therapeutic effects were evaluated after continuous treatment for 12 weeks. The lung function, clinical efficacy, airway remodeling indexes, inflammatory factors, immune function and adverse drug reactions were compared between the two groups.Results The differences of forced vital capacity (FVC), peak expiratory flow (PEF) and forced expiratory volume in one second (FEV₁) / FVC before and after the treatment were not significantly different between the two groups (P > 0.05). There was no significant difference in the overall effective rate between the two groups (P > 0.05). The differences of the ratio of airway wall thickness to outer diameter and the wall area percentage before and after treatment were not significantly different between the two groups (P > 0.05). The differences of the levels of C-reactive protein, serum amyloid A and interleukin-17 before and after the treatment were not significantly different between the two groups (P > 0.05). The difference of the CD4⁺/CD8⁺ ratio before and after the treatment was not different between the two groups (P > 0.05). There was no significant difference in the overall incidence of adverse reactions between the two groups (P > 0.05).Conclusion The efficacy of budesonide / glycopyrrolate / formoterol fumarate is comparable to that of indacaterol/ glycopyrrolate in the treatment of COPD. Both of them could significantly enhance the lung function, inhibit inflammatory responses, improve the immune function, and prevent airway remodeling with a good safety profile.